Phynova's PYN17 granted UK Patent
Botanical Hepatitis C treatment PYN17
LONDON (AFX) - Phynova Group PLC, which develops Western pharmaceuticals based on Chinese medicines, said it has received its first UK patent for PYN17, a botanical drug for the treatment of Hepatitis C.
PYN17 contains extracts of four plants that reduce liver inflammation, improves hepatic function and stimulates the immune system. It is designed to treat the symptoms of chronic hepatitis C viral infections.
There are no adequate treatments currently available to manage these disease symptoms. The global market for the treatment of Hepatitis C is estimated to be worth 9 bln usd by 2010.
Phynova is planning to have a multi-centred Phase IIb clinical trial underway in the US in early 2007.
Phynova currently has three other patent applications pending, PYN22, an anti-obesity product, PYN18, an antiviral for the treatment of Hepatitis C and PYN5c, a treatment for SARS.
LONDON (AFX) - Phynova Group PLC, which develops Western pharmaceuticals based on Chinese medicines, said it has received its first UK patent for PYN17, a botanical drug for the treatment of Hepatitis C.
PYN17 contains extracts of four plants that reduce liver inflammation, improves hepatic function and stimulates the immune system. It is designed to treat the symptoms of chronic hepatitis C viral infections.
There are no adequate treatments currently available to manage these disease symptoms. The global market for the treatment of Hepatitis C is estimated to be worth 9 bln usd by 2010.
Phynova is planning to have a multi-centred Phase IIb clinical trial underway in the US in early 2007.
Phynova currently has three other patent applications pending, PYN22, an anti-obesity product, PYN18, an antiviral for the treatment of Hepatitis C and PYN5c, a treatment for SARS.
0 comments:
Post a Comment